Kangmei Pharmaceutical600518.SHValuation Analysis

As of Oct 19, 2026, Kangmei Pharmaceutical (600518.SH) trades at a P/E of 610.00x, P/B of 2.46x, P/S of 3.92x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 78th percentile over the trailing 10Y window (vs. 41st percentile over 3Y); P/B sits at the 24th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 39th percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 99th percentile within its industry and the 98th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Notably, P/E and P/B aren't telling quite the same story, 53.3 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Kangmei Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.